Limit permissible forms of medical cannabis to pills or liquid tinctures and clarify provisions relating to medical cannabis
LB483 would substantially revise Nebraska’s medical cannabis laws by narrowing the forms of medical cannabis that may be used to pills or liquid tinctures. It also rewrites and clarifies a number of definitions in the Nebraska Medical Cannabis Patient Protection Act, including terms such as allowable amount, cannabis, cannabis accessories, caregiver, qualified patient, THC, and written recommendation. The bill sets a specific allowable amount of cannabis products, including products containing up to 300 milligrams of delta-9 THC and five ounces of cannabis, and excludes the weight of other ingredients in topical or oral preparations from that calculation.
The bill also makes conforming changes across Nebraska’s controlled substances, drug paraphernalia, hemp transport, and cannabis tax provisions. It updates criminal penalties and exceptions so that medical cannabis activity authorized under the medical cannabis laws is carved out from otherwise applicable marijuana and controlled-substance prohibitions, and it removes medical cannabis from the marijuana and controlled substances tax. In addition, LB483 revises the structure and ethics rules for the Nebraska Liquor Control Commission and the Nebraska Medical Cannabis Commission, including appointment, conflict-of-interest, and gift restrictions, and it repeals several original and revised statutory sections while declaring an emergency so the act would take effect immediately upon passage.
LB483 would change state law by tightening the permitted delivery forms of medical cannabis, redefining key terms in the medical cannabis statutes, and aligning criminal, tax, and regulatory provisions with the medical cannabis framework. It would affect qualified patients, caregivers, health care practitioners, dispensary-related actors, law enforcement, and the Nebraska Liquor Control Commission/Medical Cannabis Commission. The bill also would remove medical cannabis from the marijuana and controlled substances tax provisions and make related conforming amendments to controlled substances and paraphernalia laws.
No committee transcript or recorded vote information was provided, so the public sentiment can only be inferred from the bill’s content and procedural history. The bill appears to reflect a regulatory and clarifying approach to medical cannabis rather than a broad expansion, suggesting an effort to impose tighter limits and administrative structure. Its eventual indefinite postponement indicates that the proposal did not advance, but the available record does not show direct debate or a documented vote count.
The main point of contention appears to be the bill’s restriction of medical cannabis to pills or liquid tinctures, which would exclude other forms that patients or advocates might prefer. Another likely issue is the bill’s broader restructuring of cannabis regulation, including changes to possession limits, tax treatment, and commission governance, which could draw concern from both medical cannabis supporters and opponents. Because no transcripts are available, specific objections cannot be attributed to named legislators or stakeholders, but the bill’s scope suggests tension between access, regulation, and enforcement priorities.